Mitesco Pivots to Tech Post-Clinic Failure, Restructures $24M Debt

TL;DR

**MITI's S-1 is a red flag: massive dilution from selling shareholders, a failed prior business, and a highly speculative pivot to tech with no clear path to profitability.**

AI Summary

Mitesco, Inc. (MITI) filed an S-1 on December 31, 2025, primarily for the resale of up to 106,836,091 shares of common stock by Selling Stockholders. The company is not selling any securities and will not receive proceeds from this offering. MITI, a smaller reporting company, has undergone significant business model changes, shifting from operating 'The Good Clinic' medical facilities, which were closed in Q4 2022 due to lack of profitability, to becoming a holding company focused on technology. Its new wholly-owned business units, Centcore, LLC and Vero Technology Ventures, LLC (VTV), were formed in June 2024. Centcore provides data center services, including cloud computing and application hosting, through a co-location agreement in Melbourne, Florida, with plans for global expansion and smaller data center development. VTV is pursuing investment and acquisition opportunities in cloud computing and data centers, actively developing an AI-based application set, 'Robo Agent,' expected for initial users in Q4 FY2025, and a new application for sports property listings by late FY2026. The company completed a significant debt restructuring in FY2024, converting approximately $24 million of obligations, including $21.5 million in senior securities and $2.5 million in notes and accounts payable, into 2,628,179 shares of restricted Common Stock and 562,998 Series A Preferred stock, at a $4.00 per share valuation for common stock. The last reported closing price of MITI's Common Stock on the OTC-QB Venture Market was $0.10 on December 26, 2025.

Why It Matters

This S-1 filing signals a critical juncture for Mitesco, Inc., as it formalizes a complete strategic pivot from healthcare clinics to a technology holding company. For investors, the resale of over 106 million shares by Selling Stockholders, without the company receiving any proceeds, suggests potential dilution and downward pressure on the already low stock price of $0.10. Employees and customers of the former 'The Good Clinic' operations have already been impacted by the closure, while new hires in Centcore and VTV face the challenges of a nascent business model in a competitive tech landscape. The broader market will watch if MITI's shift into data centers and AI can generate sustainable revenue, especially given its history of unprofitability and the highly speculative nature of its new ventures, competing with established cloud providers and AI developers.

Risk Assessment

Risk Level: high — The risk level is high due to several factors: the company's prior business, 'The Good Clinic,' was closed in Q4 2022 due to a 'lack of profitability,' indicating a history of failed ventures. The S-1 registers 106,836,091 shares for resale by Selling Stockholders, with the company receiving no proceeds, which could lead to significant dilution for existing shareholders. Furthermore, the Common Stock trades on the OTC-QB Venture Market at a low price of $0.10 as of December 26, 2025, highlighting its speculative nature and limited liquidity.

Analyst Insight

Investors should exercise extreme caution and consider avoiding MITI shares. The significant volume of shares registered for resale by Selling Stockholders, coupled with the company's history of failed operations and highly speculative new ventures in data centers and AI, presents substantial downside risk. Wait for clear evidence of sustained revenue generation and profitability from the new business units before considering any investment.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• 106,836,091 — Shares of Common Stock (Maximum shares registered for resale by Selling Stockholders, indicating potential dilution.)
• $0.10 — Common Stock Closing Price (Last reported closing price on OTC-QB Venture Market on December 26, 2025, highlighting low valuation.)
• $24 million — Total Obligations Restructured (Amount of senior securities, notes, and accounts payable converted in FY2024 debt restructuring.)
• 2,628,179 — Restricted Common Stock Shares (Shares issued in connection with restructuring of approximately $12.5 million in financial obligations.)
• 562,998 — Series A Preferred Stock Shares (Shares issued to institutional investors in exchange for over $14 million of Series D and F Preferred Shares.)
• $4.00 — Common Stock Valuation Price (Price per share used for converting certain obligations into common stock during restructuring.)
• Q4 FY2025 — Robo Agent Availability (Expected initial user availability for VTV's AI-based application.)
• late FY2026 — Sports Application Completion (Expected completion date for the new application related to sports and pickleball arena.)
• $10,000 — Consulting Rate (Monthly rate for the executive developing the Robo Agent product set, starting August 2025.)
• 8 — Data Centers (Number of other data centers worldwide with relationships to Centcore's Melbourne, Florida co-location partner.)

Key Players & Entities

• Mitesco, Inc. (company) — Registrant and issuer of common stock
• Mack Leath (person) — Chief Executive Officer of Mitesco, Inc.
• Joel D. Mayersohn, Esq. (person) — Legal counsel for Mitesco, Inc.
• Frank Borger Gilligan, Esq. (person) — Legal counsel for Mitesco, Inc.
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Centcore, LLC (company) — Wholly-owned business unit providing data center services
• Vero Technology Ventures, LLC (company) — Wholly-owned business unit for tech investments and AI development
• The Good Clinic (company) — Former operating subsidiary focused on medical clinics, now discontinued
• $12.5 million (dollar_amount) — Value of financial obligations restructured into common stock
• $14 million (dollar_amount) — Value of Series D and Series F Preferred Shares exchanged for Series A Preferred Stock

FAQ

Risk Factors

• Business Model Transformation Risk [high — operational]: Mitesco has undergone a significant business model shift from operating 'The Good Clinic' medical facilities, which were closed in Q4 2022 due to lack of profitability, to a holding company focused on technology. This transition introduces inherent risks associated with establishing and scaling new business units, Centcore and VTV, in the technology sector.
• Dependence on Selling Stockholders [high — financial]: The S-1 filing is for the resale of up to 106,836,091 shares by Selling Stockholders, and the company will not receive any proceeds. This large volume of shares could lead to significant downward pressure on the stock price, especially given the current low trading price of $0.10.
• Debt Restructuring and Dilution [medium — financial]: The company completed a significant debt restructuring in FY2024, converting approximately $24 million of obligations into 2,628,179 shares of restricted Common Stock and 562,998 Series A Preferred stock. While this addressed debt, the conversion at a $4.00 per share valuation for common stock, compared to the current $0.10 trading price, highlights potential future dilution and the significant difference in perceived value.
• New Technology Product Development Risk [medium — market]: Vero Technology Ventures, LLC (VTV) is actively developing an AI-based application set, 'Robo Agent,' expected for initial users in Q4 FY2025, and a new application for sports property listings by late FY2026. The success and timely delivery of these new technology products are critical for future revenue generation and are subject to development risks, market adoption, and competitive pressures.
• Data Center Operations and Expansion [medium — operational]: Centcore, LLC provides data center services through a co-location agreement in Melbourne, Florida, with plans for global expansion and smaller data center development. The success of these operations depends on the reliability of infrastructure, securing new agreements, and managing expansion effectively, especially given the existing relationships with 8 other data centers worldwide.
• Limited Operating History in New Segments [medium — financial]: As a newly formed holding company with technology-focused business units (Centcore and VTV) established in June 2024, Mitesco has a very limited operating history in its current business model. This lack of established performance in its new segments makes financial projections and future performance difficult to assess.
• Executive Compensation for Product Development [low — financial]: An executive is receiving a monthly consulting rate of $10,000 starting August 2025 for developing the Robo Agent product set. While necessary for development, this represents a significant ongoing cost for a product not yet generating revenue.

Industry Context

Mitesco is pivoting into the technology sector, specifically focusing on data center services (Centcore) and technology investments/development (VTV). The data center market is competitive, driven by increasing demand for cloud computing, AI, and data storage. VTV's focus on AI applications and sports property listings targets emerging or niche markets within the broader tech landscape. The company faces competition from established cloud providers, specialized data center operators, and other technology startups.

Regulatory Implications

As a smaller reporting company, Mitesco has fewer disclosure requirements. However, the S-1 filing itself is a significant regulatory event, registering a large number of shares for resale. The company must comply with SEC regulations regarding public filings and disclosures, especially concerning its business transformation and new ventures. Any future offerings or material changes will require further regulatory scrutiny.

What Investors Should Do

1. Monitor 'Robo Agent' and Sports App Development
2. Assess Market Impact of Resale Shares
3. Evaluate Centcore's Data Center Expansion Strategy
4. Scrutinize Financials Post-Transformation

Key Dates

• 2022-10-01: Closure of 'The Good Clinic' operations — Marked the end of Mitesco's previous business model due to lack of profitability, necessitating a strategic pivot.
• 2024-06-01: Formation of Centcore, LLC and Vero Technology Ventures, LLC — Established the new technology-focused business units that form the core of Mitesco's current strategy.
• 2024-12-31: Completion of Debt Restructuring — Approximately $24 million in obligations were converted into equity, addressing immediate debt concerns but potentially increasing share count.
• 2025-12-26: Common Stock Closing Price of $0.10 — Indicates a significantly low market valuation for the company's common stock.
• 2025-12-31: S-1 Filing Date — Registered up to 106,836,091 shares for resale by Selling Stockholders, signaling potential future market overhang.
• 2025-10-01: Expected initial user availability for 'Robo Agent' — Key milestone for VTV's AI product development, crucial for future revenue generation.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This filing is specifically for the resale of shares by existing stockholders, not for raising new capital for Mitesco.)

Smaller Reporting Company

A classification by the SEC for companies that meet certain thresholds for public float and revenue. These companies have fewer disclosure requirements compared to larger public companies. (MITI's status as an SRC may affect the depth of information available and the complexity of its regulatory obligations.)

Selling Stockholders

Existing shareholders who are offering to sell their shares of a company's stock to the public, as opposed to the company itself selling new shares. (The primary purpose of this S-1 filing is to allow these stockholders to sell their shares, which could impact market supply and price.)

Co-location Agreement

An arrangement where a company rents space, power, and cooling in a data center facility owned by another party, allowing them to house their own servers and networking equipment. (Centcore utilizes this model for its data center services, relying on a partner facility in Melbourne, Florida.)

Debt Restructuring

The process of modifying the terms of existing debt obligations to improve a company's financial health, often involving converting debt into equity or extending repayment periods. (Mitesco recently restructured approximately $24 million of debt, converting it into company stock and preferred shares.)

OTC-QB Venture Market

A quotation service operated by OTC Markets Group for early-stage and development stage companies that have limited financial disclosure and are not listed on major exchanges like the NYSE or Nasdaq. (Mitesco's common stock is currently traded on this market, which typically implies lower liquidity and higher volatility.)

Series A Preferred Stock

A class of preferred stock that has rights and privileges senior to common stock. It is often issued in private placements or during restructuring events. (Mitesco issued Series A Preferred Stock as part of its debt restructuring, indicating a complex capital structure.)

Year-Over-Year Comparison

This S-1 filing represents a significant strategic shift from Mitesco's previous operations ('The Good Clinic') to a technology-focused holding company. Unlike prior filings that might have detailed healthcare operations, this document focuses on the nascent technology businesses, Centcore and VTV. Key metrics such as revenue, margins, and net income are not readily available in this filing for comparison, as the company is in the early stages of its new business model. The primary focus is on the resale of shares by existing stockholders, highlighting a potential overhang rather than new capital infusion.

Key Financial Figures

• $0.01 — 6,091 shares of common stock, par value $0.01 per share (the "Common Stock") of Mites
• $12.5 million — with the restructuring of approximately $12.5 million worth of financial obligations includin
• $14 million — tutional investors in exchange for over $14 million worth of its Series D and Series F Pref
• $0.10 — d closing price of our Common Stock was $0.10. There is currently no trading history
• $10,000 — set on a consulting basis at a rate of $10,000 per month. We have also recruited three
• $30 million — of June 30, 2024, the Company had over $30 million in senior securities, notes and account
• $4.00 — common stock using a price per share of $4.00. As of the date of this filing it has
• $2.5 million — ts senior securities, and approximately $2.5 million of notes and accounts payable, into 2,6
• $4 — ected to receive common stock using the $4 per share valuation. 2 Table of Conte
• $580,132 — ents pursuant to which it has converted $580,132, including $32,132 of principal and int
• $32,132 — ch it has converted $580,132, including $32,132 of principal and interest, of its 2024
• $100,000 — stock were issued for consideration of $100,000; The Q2 redemptions of Series A Prefe
• $25,000 — were issued for total consideration of $25,000. As part of the restructuring, the Co
• $1 m — L.P. with a potential total funding of $1 million, with an initial funding of $250,
• $250,000 — $1 million, with an initial funding of $250,000. Under the terms of the 18 month note,

Filing Documents

• mitis1122925.htm (S-1) — 2639KB
• mitiex5-1.htm (EX-5.1) — 8KB
• mitiex23-1.htm (EX-23.1) — 3KB
• mitiex-fee.htm (EX-FILING FEES) — 14KB
• image_001.jpg (GRAPHIC) — 3KB
• image_002.jpg (GRAPHIC) — 50KB
• image_003.jpg (GRAPHIC) — 9KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• ex5-1_002.jpg (GRAPHIC) — 12KB
• ex23-1_001.jpg (GRAPHIC) — 16KB
• ex23-1_002.jpg (GRAPHIC) — 21KB
• 0001185185-25-002208.txt ( ) — 13009KB
• miti-20250930.xsd (EX-101.SCH) — 97KB
• miti-20250930_cal.xml (EX-101.CAL) — 73KB
• miti-20250930_def.xml (EX-101.DEF) — 498KB
• miti-20250930_lab.xml (EX-101.LAB) — 771KB
• miti-20250930_pre.xml (EX-101.PRE) — 532KB
• mitis1122925_htm.xml (XML) — 1593KB
• mitiex-fee_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 8 MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY 18 DIVIDEND POLICY 18

USE OF PROCEEDS

USE OF PROCEEDS 18

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 23 DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 30

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 34 DIRECTOR COMPENSATION 35

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 36 SELLING STOCKHOLDERS 37 DESCRIPTION OF OUR CAPITAL STOCK 44 PLAN OF DISTRIBUTION 49 EXPERTS 50 LEGAL MATTERS 50 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT 50 WHERE YOU CAN FIND MORE INFORMATION 51 INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a Registration Statement on Form S-1 that we filed with the SEC. The Stockholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the securities described in this prospectus. You should rely only on the information contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the SEC. Neither we nor the Selling Stockholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus, or any applicable prospectus supplement or any free writing prospectuses prepared by us or on our behalf and filed with the SEC. We take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. The Stockholders are offering to sell our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amend

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This registration statement, of which this prospectus forms a part, contains forward-looking statements. All statements other than statements of historical fact contained herein, including are forward-looking statements. Words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that," "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions, as well as statements in future tense, are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will actually be achieved. Forward-looking statements are based on information we have when those statements are made or our management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to: we will need to raise additional capital to fund our operations in furtherance of our business plan; we have an evolving business model, which increases the complexity of our business; our data center co-location and software services operations present a number of risks; our holding company model presents certain additional risks; our growth strategy is subject to a significant degree of risk; we are heavily dependent on our senior management, and a loss of a member of our senior management team could cause our stock price to suffer; if we fail to anticipate and adequately respond to rapid technological change

View Full Filing

View this S-1 filing on SEC EDGAR